Haleon Stock (NYSE:HLN)


OwnershipChartTranscripts

Previous Close

$9.88

52W Range

$8.86 - $11.42

50D Avg

$10.49

200D Avg

$10.03

Market Cap

$43.72B

Avg Vol (3M)

$15.53M

Beta

0.23

Div Yield

$0.17 (0.01%)

HLN Company Profile


Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Brentford, the United Kingdom.

Show More

Industry

Drug Manufacturers - Specialty & Generic

Sector

Healthcare

Exchange

NYSE

ADR

Yes

Country

GB

Employees

24,561

IPO Date

Jul 25, 2022

Website

HLN Performance


Latest Earnings Call Transcripts


Q1 25May 02, 25 | 3:30 PM
Q4 24Feb 27, 25 | 4:00 AM
Q2 24Aug 02, 24 | 4:00 AM

Peer Comparison


TickerCompany
OGNOrganon & Co.
KDKyndryl Holdings, Inc.
TAKTakeda Pharmaceutical Company Limited
WDSWoodside Energy Group Ltd
EBSEmergent BioSolutions Inc.
ZTSZoetis Inc.
VTRSViatris Inc.
GSKGSK plc
ELANElanco Animal Health Incorporated